AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12170853 — intervention group
Group type: COMPARATOR
Intervention: Southern group
Number of subjects: 72
Study 12170853 — intervention group
Group type: COMPARATOR
Intervention: ITI group
Number of subjects: 72
Study 12170853 — intervention group
Group type: COMPARATOR
Intervention: Steri-Oss group
Number of subjects: 72
Study 10221686 — intervention group
Group type: COMPARATOR
Intervention: 100 IU FSH
Number of subjects: 199
Study 10221686 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU FSH
Number of subjects: 199
Study 8552232 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB receptor agonist) administered pre-operatively with morphine (mu-opioid analgesic)
Number of subjects: 0
Study 8552232 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB receptor agonist) administered with pentazocine (kappa-opioid analgesic)
Number of subjects: 0
Study 8552232 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (kappa-opioid analgesic)
Number of subjects: 0
Study 2364407 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 1,000 ppm fluoride (NaF or Na2PO3F)
Number of subjects: 8
Study 2364407 — intervention group
Group type: COMPARATOR
Intervention: Dicalcium phosphate dihydrate toothpaste
Number of subjects: 8
Study 2364407 — intervention group
Group type: COMPARATOR
Intervention: Other toothpastes (chalk, silica or alumina with sodium monofluorophosphate, silica with sodium fluoride)
Number of subjects: 8
Study 6107097 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45
Number of subjects: 64
Study 6107097 — intervention group
Group type: COMPARATOR
Intervention: pancuronium
Number of subjects: 64
Study 6107097 — intervention group
Group type: COMPARATOR
Intervention: alcuronium
Number of subjects: 64
Study 6107097 — intervention group
Group type: COMPARATOR
Intervention: tubocurarine
Number of subjects: 64
Study 30377187 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-DPP
Number of subjects: 378
Study 30377187 — intervention group
Group type: COMPARATOR
Intervention: VA-DPP
Number of subjects: 378
Study 30377187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DPPs
Number of subjects: 378
Study 27552802 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session focusing on the importance of adherence to medication (30 minutes)
Number of subjects: 446
Study 27552802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 446
Study 24893602 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time assessment of predictors (motivation for quitting, smoking expectancies, quit self-efficacy, smoking urges, negative affect, positive affect, restlessness, hostility, and stress) during the 6 days prior to a scheduled quit attempt.
Number of subjects: 57
Study 22829691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose etanercept (25 mg/week)
Number of subjects: 70
Study 22829691 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose etanercept (50 mg/week)
Number of subjects: 70
Study 22829691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Low-dose and Standard-dose etanercept)
Number of subjects: 70
Study 20833514 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (mean dose 10.9 mg)
Number of subjects: 49
Study 20833514 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone (mean dose 88.9 mg)
Number of subjects: 49
Study 20833514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine to Ziprasidone switch (mean dose 136 mg)
Number of subjects: 49
Study 20833514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone to Olanzapine switch (mean dose 16 mg)
Number of subjects: 49
Study 18655723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking programme combined with physical activity consultations
Number of subjects: 0
Study 18655723 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control for 12 weeks (followed by minimal pedometer-based intervention)
Number of subjects: 0
Study 15905753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16
Study 15905753 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 16
Study 12629228 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V PET in patients with temporal lobe epilepsy
Number of subjects: 22
Study 12629228 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V in patients with temporal lobe epilepsy
Number of subjects: 22
Study 12629228 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V asymmetry index (AI) in ILT
Number of subjects: 22
Study 12629228 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V AI in IMT
Number of subjects: 22
Study 11202292 — intervention group
Group type: EXPERIMENTAL
Intervention: Open abdomen method (OAM)
Number of subjects: 50
Study 8822756 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (two non-filtered cigarettes for 4 minutes)
Number of subjects: 18
Study 8822756 — intervention group
Group type: COMPARATOR
Intervention: Control (not smoking)
Number of subjects: 18
Study 1582456 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Number of subjects: 52
Study 1582456 — intervention group
Group type: COMPARATOR
Intervention: Non-osteosynthesis
Number of subjects: 52
Study 1582456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 6734209 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380Ag
Number of subjects: 2762
Study 6734209 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 220C
Number of subjects: 2762
Study 6734209 — intervention group
Group type: COMPARATOR
Intervention: Mahua double ring
Number of subjects: 2762
Study 6734209 — intervention group
Group type: COMPARATOR
Intervention: Mahua device
Number of subjects: 2762
Study 29300423 — intervention group
Group type: EXPERIMENTAL
Intervention: RE plus dairy protein and micronutrient supplementation
Number of subjects: 82
Study 29300423 — intervention group
Group type: COMPARATOR
Intervention: RE only
Number of subjects: 82
Study 26427866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (LE; 1:80,000)
Number of subjects: 72
Study 26427866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with clonidine (LC; 15 mcg/ml)
Number of subjects: 72
Study 26427866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (LE; 1:80,000) and Lidocaine with clonidine (LC; 15 mcg/ml)
Number of subjects: 72
Study 1467204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 1467204 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 1467204 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 0
Study 22083026 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training toward threat
Number of subjects: 49
Study 22083026 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training away from threat
Number of subjects: 49
Study 22083026 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 49
Study 20412218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry wash shampooing (DW)
Number of subjects: 67
Study 20412218 — intervention group
Group type: COMPARATOR
Intervention: Regular wash shampooing
Number of subjects: 67
Study 18238740 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 0
Study 15841875 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalization measure
Number of subjects: 549
Study 15841875 — intervention group
Group type: COMPARATOR
Intervention: Other affect-related measures
Number of subjects: 549
Study 15841875 — intervention group
Group type: COMPARATOR
Intervention: History of major depression
Number of subjects: 549
Study 12427351 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite stress management intervention focused on enhancing positive coping styles and decreasing negative coping styles.
Number of subjects: 95
Study 12427351 — intervention group
Group type: COMPARATOR
Intervention: Control group with delayed intervention.
Number of subjects: 95
Study 10769603 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus (300 mg capsules, 3 capsules thrice daily)
Number of subjects: 57
Study 10769603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (antacid powder in similar capsule form)
Number of subjects: 57
Study 7562263 — intervention group
Group type: EXPERIMENTAL
Intervention: mapping-enhanced counseling
Number of subjects: 93
Study 7562263 — intervention group
Group type: COMPARATOR
Intervention: standard counseling
Number of subjects: 93
Study 1777551 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone with glucose and sodium citrate (1:1:1 by weight)
Number of subjects: 0
Study 1777551 — intervention group
Group type: COMPARATOR
Intervention: Azapropazone alone
Number of subjects: 0
Study 1777551 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone with glucose and sodium citrate
Number of subjects: 0
Study 6846115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg
Number of subjects: 25
Study 6846115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 25
Study 6846115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6846115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (both doses)
Number of subjects: 25
Study 6846115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 25
Study 29505385 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 68
Study 29505385 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 68
Study 28252471 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training with a dynamometric platform
Number of subjects: 43
Study 28252471 — intervention group
Group type: COMPARATOR
Intervention: Control group training without a dynamometric platform
Number of subjects: 43
Study 27764151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful breathing condition (n = 12)
Number of subjects: 36
Study 27764151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal condition (contrast group, n = 12)
Number of subjects: 36
Study 27764151 — intervention group
Group type: COMPARATOR
Intervention: Non-training condition (control group, n = 12)
Number of subjects: 36
Study 25063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal during a socially evaluative speech task (Experiment 1)
Number of subjects: 184
Study 25063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal during a physical pain cold pressor task (Experiment 2)
Number of subjects: 184
Study 25063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (Experiment 2)
Number of subjects: 184
Study 25063879 — intervention group
Group type: COMPARATOR
Intervention: Control condition (both experiments)
Number of subjects: 184
Study 22150099 — intervention group
Group type: EXPERIMENTAL
Intervention: Female physicians providing care to female patients
Number of subjects: 509
Study 22150099 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patient-female physician dyad
Number of subjects: 509
Study 22150099 — intervention group
Group type: COMPARATOR
Intervention: Male patient-male physician dyad
Number of subjects: 509
Study 18435867 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling scheme
Number of subjects: 0
Study 22024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hüttenbrink's method (Group 1)
Number of subjects: 125
Study 22024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Author's method (Group 2)
Number of subjects: 125
Study 15788107 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 ml red wine daily for 2 weeks
Number of subjects: 20
Study 12477587 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 50
Study 12477587 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 50
Study 10512406 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-Fr nasogastric tube
Number of subjects: 29
Study 10512406 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Fr nasogastric tube
Number of subjects: 29
Study 10512406 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Fr nasogastric tube
Number of subjects: 29
Study 10512406 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no nasogastric tube)
Number of subjects: 29
Study 7557176 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 140
Study 7557176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1835850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexa‐CAF (hexamethylmelamine, cyclophosphamide, methotrexate, 5‐fluorouracil)
Number of subjects: 377
Study 1835850 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP‐5 (cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin for 5 days)
Number of subjects: 377
Study 1835850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (retreatment)
Number of subjects: 377
Study 1835850 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy with cisplatin
Number of subjects: 377
Study 1835850 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 tumours (well differentiated)
Number of subjects: 377
Study 1835850 — intervention group
Group type: COMPARATOR
Intervention: Other grades of tumours
Number of subjects: 377
Study 1835850 — intervention group
Group type: COMPARATOR
Intervention: Microscopic disease at second‐look
Number of subjects: 377
Study 1835850 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 377
Study 7039400 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline depot tablets 7.5 mg twice a day
Number of subjects: 0
Study 7039400 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline tablets 5 mg three times a day
Number of subjects: 0
Study 31727415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 0.5 mg/d
Number of subjects: 235
Study 31727415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 1 mg/d
Number of subjects: 235
Study 31727415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/d
Number of subjects: 235
Study 31727415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 31727415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 0.02 mg/drospirenone 3 mg (reference drug)
Number of subjects: 235
Study 29065707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (5×10^9 cfu)
Number of subjects: 219
Study 29065707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 27419081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger powder supplementation (1 g/d)
Number of subjects: 120
Study 27419081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg starch)
Number of subjects: 120
Study 23824624 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive women
Number of subjects: 96
Study 23824624 — intervention group
Group type: COMPARATOR
Intervention: CIN2/3
Number of subjects: 96
Study 23258609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light intervention (2,500 lux for 45-60 min)
Number of subjects: 22
Study 23258609 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 20726255 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV (HDC) vaccine
Number of subjects: 1200
Study 20726255 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 1200
Study 18158289 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2022
Study 18158289 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2022
Study 16171661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia (HEA) with bupivacaine (n = 20)
Number of subjects: 40
Study 16171661 — intervention group
Group type: COMPARATOR
Intervention: Hypotensive total intravenous anesthesia (HTIVA) with propofol and remifentanil (n = 20)
Number of subjects: 40
Study 12606177 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 mg sublingually for 12 months; supervised daily administration for at least 6 months, possible take-home doses thereafter)
Number of subjects: 40
Study 12606177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tapered 6 day regimen of buprenorphine followed by placebo)
Number of subjects: 40
Study 10531156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI, 1.76 mg (250 microg ex-valve, 220 microg ex-actuator)
Number of subjects: 14
Study 10531156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI with 750-mL spacer
Number of subjects: 14
Study 10531156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI, 250 microg
Number of subjects: 14
Study 10531156 — intervention group
Group type: COMPARATOR
Intervention: Placebo by pMDI
Number of subjects: 14
Study 10531156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI
Number of subjects: 14
Study 10531156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI with spacer
Number of subjects: 14
Study 8759811 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic waveforms with reversed polarity
Number of subjects: 26
Study 8759811 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with reversed polarity
Number of subjects: 26
Study 8759811 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic waveforms with reversed polarity in high threshold subgroup
Number of subjects: 26
Study 8759811 — intervention group
Group type: COMPARATOR
Intervention: Biphasic waveforms
Number of subjects: 26
Study 1834093 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5‐20 mg daily)
Number of subjects: 27
Study 1834093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7035545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Spironolactone
Number of subjects: 90
Study 7035545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (spironolactone and furosemide)
Number of subjects: 90
Study 7035545 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 90
Study 31888571 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit data
Number of subjects: 18999
Study 31888571 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-audit data
Number of subjects: 18999
Study 31888571 — intervention group
Group type: COMPARATOR
Intervention: Pre-audit data
Number of subjects: 18999
Study 29727056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Midazolam (group A)
Number of subjects: 152
Study 29727056 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group B)
Number of subjects: 152
Study 26547918 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1469
Study 26547918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1469
Study 25453457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg plus clopidogrel 75 mg
Number of subjects: 2916
Study 25453457 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg plus placebo
Number of subjects: 2916
Study 25453457 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target <130 mm Hg
Number of subjects: 2916
Study 25453457 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure target 130-149 mm Hg
Number of subjects: 2916
Study 22307842 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels
Number of subjects: 772
Study 21336429 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid‐enriched oral nutritional supplement (2 packs per day for 12 weeks) plus dietary counseling
Number of subjects: 13
Study 21336429 — intervention group
Group type: COMPARATOR
Intervention: Control group (only dietary counseling)
Number of subjects: 13
Study 18349032 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and dietary advice (ED)
Number of subjects: 73
Study 18349032 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only program (EX)
Number of subjects: 73
Study 15920225 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 264/0.45 (up to 45 mL/kg)
Number of subjects: 50
Study 15920225 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin (up to 45 mL/kg)
Number of subjects: 50
Study 12045866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 0
Study 12045866 — intervention group
Group type: COMPARATOR
Intervention: Rossetti fundoplication
Number of subjects: 0
Study 12045866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 0
Study 9669185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg a day
Number of subjects: 436
Study 9669185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 7634612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed lavage irrigation
Number of subjects: 12
Study 7634612 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation (Control)
Number of subjects: 12
Study 2374564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active injections of suspected allergens (60 total injections)
Number of subjects: 18
Study 2374564 — intervention group
Group type: COMPARATOR
Intervention: Control injections (180 total injections)
Number of subjects: 18
Study 2374564 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing doses given by physicians (both suspected allergen and saline)
Number of subjects: 18
Study 16635 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 7
Study 16635 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium 100 mg
Number of subjects: 7
Study 16635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloralphenazone 1300 mg
Number of subjects: 7
Study 31186035 — intervention group
Group type: EXPERIMENTAL
Intervention: AT supplementation to maintain a functional AT level between 80 and 120%
Number of subjects: 0
Study 31186035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AT supplementation)
Number of subjects: 0
Study 28239939 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sitagliptin 100 mg plus fasiglifam 25 mg
Number of subjects: 368